no statement of use filed
on 17 Oct 2016
Last Applicant/ Owned by
Suite 1500
New York
NY
10016
Serial Number
86539348 filed on 19th Feb 2015
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
"PHARM"
Color is not claimed as a feature of the mark. Software for measuring prescription costs and forecasting catastrophic loses within populations of patients, which analysis provides a financial quote for self-insured, prescription plans seeking insurance to cover unexpected cost increases among their populations The mark consists of an image of two (2) shaded, vertically-positioned, partially-overRead More
Software for measuring prescription costs and forecasting catastrophic loses within populations of patients, which analysis provides a financial quote for self-insured, prescription plans seeking insurance to cover unexpected cost increases among their populations
No 86539348
No Service/Collective Mark
No 42817-002000
No
No
No
No
No
No
No
No
10.09.01 -
Medicines and nonmedical products in tablet, capsule or powder form; suppositories
26.03.13 -
Two ovals
The mark consists of an image of two (2) shaded, vertically-positioned, partially-overlapping, pharmaceutical pill capsules, wherein the overlapping area is about 2/3 of each capsule, wherein the overlapping-exterior boundaries of the capsules are illustrated as non-shaded lines, followed by the phrase 'Pharm Re'.
| Status Date | Action Taken |
|---|---|
| 17th Oct 2016 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
| 17th Oct 2016 | ABANDONMENT - NO USE STATEMENT FILED |
| 09th Mar 2016 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 07th Mar 2016 | TEAS EXTENSION RECEIVED |
| 07th Mar 2016 | EXTENSION 1 GRANTED |
| 07th Mar 2016 | EXTENSION 1 FILED |
| 03rd Mar 2016 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 03rd Mar 2016 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 02th Mar 2016 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 02th Mar 2016 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
